Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Zigmond
M J
MJ
Department of Behavioral Neuroscience, University of Pittsburgh, Pennsylvania 15260.
Hastings
T G
TG
Abercrombie
E D
ED
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009498:Neurotoxins / Q000633:toxicity*; D016627:Oxidopamine / Q000633:toxicity*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats
D009498:Neurotoxins; D007980:Levodopa; D016627:Oxidopamine; D004298:Dopamine